Firms May Lose Data Exclusivity Earlier Under Planned EU Adaptive Licensing Regime
This article was originally published in The Pink Sheet Daily
Executive Summary
Adaptive licensing is coming to Europe and, while it will be beneficial to patients, data exclusivity considerations may render it a double-edged sword to the innovative drug industry.
You may also be interested in...
Cancer Drug Cull By NHS Sparks Demands For NICE Reform
Disappointed by NHS England’s decision to remove a number of high-cost drugs from the Cancer Drugs Fund, the U.K. pharma industry is focusing its firepower on reforming NICE appraisals.
Adapting HTA To A Value-Based Approach: A Conversation With ABPI's Stephen Whitehead
The Association of the British Pharmaceutical Industry's chief executive says a focus on drug value rather than cost, and an adaptive approach to health technology assessment are approaches that would encourage pharma innovation.
Europe Unveils New Health Commissioner And Restructuring For Growth
The EU’s new Health Commission Vytenis Andriukaitis will need to focus on growth and competitiveness, as the new Commission redistributes responsibility for pharmaceuticals.